Nicholas Williams
Directeur/Membre du Conseil chez Alderaan Biotechnology SAS
Provenance du réseau au premier degré de Nicholas Williams
Entité | Type d'entité | Industrie | |
---|---|---|---|
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.
22
| Private Company | Investment Managers | 22 |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million.
7
| Subsidiary | Biotechnology | 7 |
Alderaan Biotechnology SAS
Alderaan Biotechnology SAS BiotechnologyHealth Technology Alderaan Biotechnology SAS operates as preclinical stage firm, that develops monoclonal antibodies for the treatment of cancer. The company was founded by Daniel Olive and Armand Bensussan on July 17, 2017 and is headquartered in Paris, France.
2
| Holding Company | Biotechnology | 2 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Nicholas Williams via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
University of Cambridge | College/University | Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree | |
Index Ventures SA
Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Founder Private Equity Analyst Private Equity Analyst Private Equity Analyst | |
INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO Founder | |
Imperial College London | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Chairman Director/Board Member Director/Board Member | |
XO1 Ltd.
XO1 Ltd. Medical/Nursing ServicesHealth Services XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom. | Medical/Nursing Services | Founder Founder | |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Z Factor Ltd.
Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Palladio Biosciences, Inc.
Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Biotechnology | Director/Board Member Director/Board Member | |
Epsilon-3 Bio Ltd
Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
Janpix Holdings, Inc.
Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
IPSEN | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
eGenesis, Inc.
eGenesis, Inc. Miscellaneous Commercial ServicesCommercial Services eGenesis, Inc. operates research platform to deliver human transplantable cells, tissues, and organs grown in pigs. It uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation. The company was founded by George M. Church, Yang Luhan, Prashant Mali, Geoff Mackay and Guell Marc in 2015 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Kaerus Bioscience Ltd. | Chairman Director/Board Member | ||
COMPUGEN LTD. | Biotechnology | Chairman Director/Board Member | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
NormOxys, Inc.
NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Anteris Bio, Inc.
Anteris Bio, Inc. Pharmaceuticals: MajorHealth Technology Anteris Bio, Inc. develops therapies for the treatment of renal disease. The company is based in Oakland, CA. The CEO of the company is Ilan Zipkin. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Teres Bio, Inc.
Teres Bio, Inc. Pharmaceuticals: MajorHealth Technology Teres Bio, Inc. operates as a clinical stage life sciences company. It translates discoveries in inflammatory pathways into novel, topical therapies for atopic dermatitis and plaque psoriasis skin diseases. The company is headquartered in Oakland, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Aditum Bio Fund 1 LP
Aditum Bio Fund 1 LP Investment ManagersFinance Aditum Bio Fund 1 LP specializes in acquiring and developing pharmaceutical assets. The company is headquartered in San Mateo, CA. | Investment Managers | Director/Board Member Director/Board Member | |
MINERVA NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
CENTESSA PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
SDS Therapeutics Ltd.
SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Critical Pressure Ltd.
Critical Pressure Ltd. Pharmaceuticals: MajorHealth Technology Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
NOVARTIS AG | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
Human Antibody Factory Ltd.
Human Antibody Factory Ltd. BiotechnologyHealth Technology Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom. | Biotechnology | Director/Board Member Founder | |
Stx Pharma Ltd. | Director/Board Member Founder | ||
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Stealthyx Therapeutics Ltd.
Stealthyx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Stealthyx Therapeutics Ltd. operates drug delivery system technology. The company was founded by Yuti Chernajovsky and Eileen Janis Anderson in 2002 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Founder | |
UltraHuman Ltd.
UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Rebalance (Cambridge) Ltd.
Rebalance (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Inhibitaxin Ltd.
Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm. | Biotechnology | Founder Director/Board Member | |
MACROGENICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
ApcinteX Ltd.
ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Founder | |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | President Corporate Officer/Principal | |
MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member Director/Board Member | |
BEAM THERAPEUTICS INC. | Biotechnology | Director/Board Member Director/Board Member | |
Index Ventures (UK) LLP | Investment Managers | Private Equity Investor Private Equity Investor | |
AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
OncoEthix SA
OncoEthix SA Pharmaceuticals: MajorHealth Technology OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
Royaume-Uni | 22 |
Etats-Unis | 20 |
Suisse | 5 |
Pays-Bas | 4 |
France | 3 |
Sectorielle
Health Technology | 32 |
Commercial Services | 10 |
Finance | 5 |
Consumer Services | 4 |
Health Services | 2 |
Opérationnelle
Director/Board Member | 244 |
Corporate Officer/Principal | 61 |
Chairman | 49 |
Independent Dir/Board Member | 45 |
Founder | 42 |
Relations les plus connectées
Insiders | |
---|---|
Paul Sekhri | 62 |
John Maraganore | 38 |
Francesco de Rubertis | 36 |
Michèle Ollier | 33 |
Joseph Jimenez | 32 |
David Grainger | 29 |
Giuseppe Zocco | 26 |
Michael Gladstone | 23 |
Kevin Johnson | 22 |
Sanford Zweifach | 22 |
Barbara Duncan | 22 |
Mark Pruzanski | 17 |
Mark Fishman | 17 |
Alasdair Thong | 15 |
Alain Huriez | 12 |
- Bourse
- Insiders
- Nicholas Williams
- Connexions Sociétés